Compound index

Melanocortin Receptor Agonists

Bremelanotide

Also known as PT-141 · Vyleesi

FDA-approved for specific indicationsFDA-approved

Last reviewed: 2026-11-19

Overview

A cyclic melanocortin receptor agonist also known as PT-141.

Regulatory status

FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.

  • Vyleesi · Sexual Health

    Acquired, generalized hypoactive sexual desire disorder in premenopausal women, with distress and specified exclusions; not sexual-performance enhancement.

    Authoritative label record

Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

WADA prohibited status: current list and context

Evidence at a glance

Two phase 3 trials supported a narrowly defined indication; no general performance or male sexual-health approval follows.

Key sources

Indication-specific regulatory sources and editorial screen checked November 19, 2026. This is not an exhaustive systematic review; consult current labels.

Related glossary terms